Article

Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: a case report

2022-07-13

Abstract excerpt

This case report describes of a pharmacokinetic drug–drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct-acting antiviral drug, leading to cardiac toxicity. A 75-year-old man, with no cardiovascular history but a diagnosis of metastatic non-small cell lung cancer with MET exon-14 deletion and hepatitis C virus infection genotype 1A, received both crizotinib and so...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 227e99a7-81eb-5ecb-8d2a-d9b6dcfcd527
DOI: 10.22541/au.165769388.80315874/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: a case reportDOI 10.22541/au.165769388.80315874/v1Read

Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report.Semantic proximity Read

Optimizing Cardiovascular Treatment in Non-Small Cell Lung Cancer: A Comprehensive Computational Approach for Assessment of Drug-Drug Interactions between Tyrosine Kinase Inhibitors and Cardiovascular DrugsSemantic proximity Read

[A review: drug-drug interactions of epithelial growth factor receptor-tyrosine kinase inhibitors].Semantic proximity Read

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.Semantic proximity Read

Optimizing Cardiovascular Treatment in Non-Small Cell Lung Cancer: A Comprehensive Computational Approach for Assessment of Drug-Drug Interactions Between Tyrosine Kinase Inhibitors and Cardiovascular DrugsSemantic proximity Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.Semantic proximity Read

A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin.Semantic proximity Read

Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?Semantic proximity Read

Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.Semantic proximity Read

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patientsSemantic proximity Read

Pulmonary Embolism And Bradycardia in a NSCLC Patient Treated With Crizotinib For a Rare Mutation: A Case ReportSemantic proximity Read